Greater Philadelphia is home to one of the world’s most advanced and dynamic cell and gene therapy ecosystems, making it the ideal base in the United States for innovative life science companies seeking growth, talent, and infrastructure.
The region has emerged as a hub for cell and gene therapy, with over sixty companies, including five of the world’s “Top 100 to Watch.” Its strength rests on extensive scientific expertise, a robust clinical trial pipeline, leading research institutions, and exceptional access to talent. This ecosystem has generated trailblazing breakthroughs, including the first FDA-approved cell therapy, gene therapy, and aesthetic cell therapy, while continuing to attract billions in investment. Institutions such as the University of Pennsylvania and the Children’s Hospital of Philadelphia hold some of the largest global patent portfolios in this field, and more than 7,000 people are now directly employed in related positions.
Since 2018, the city has experienced an eightfold surge in biotech employment, a 150% expansion in laboratory space, and a 71% rise in NIH funding for cell and gene therapy. With state-of-the-art facilities, advanced manufacturing resources, and comprehensive workforce development programs, the region provides everything needed to bring life science innovations from the laboratory to the market.
For companies in the United Kingdom and Ireland looking to expand into the United States, Greater Philadelphia provides not only a ready-made ecosystem for success but also a gateway to the entire North American life sciences market.
